Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) have signed a strategic agreement for the scale-up and manufacturing of Emercell’s lead product.   Emercell has developed a platform technology to produce off-the-shelf natural killer (NK) cells. NK cells are highly potent immune effectors, used alone as monotherapy, or in combination with therapeutic antibodies, or are genetically engineered to produce Chimeric Antigen Receptor (CAR)-NK cells for the treatment of hematological malignancies...